KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Esperion Therapeutics (ESPR) Other Accumulated Expenses (2018 - 2023)

Esperion Therapeutics' Other Accumulated Expenses history spans 6 years, with the latest figure at $25.0 million for Q4 2023.

  • For Q4 2023, Other Accumulated Expenses rose 89.32% year-over-year to $25.0 million; the TTM value through Dec 2023 reached $25.0 million, up 89.32%, while the annual FY2023 figure was $25.0 million, 89.32% up from the prior year.
  • Other Accumulated Expenses reached $25.0 million in Q4 2023 per ESPR's latest filing, up from $13.2 million in the prior quarter.
  • In the past five years, Other Accumulated Expenses ranged from a high of $30.4 million in Q4 2021 to a low of $3.2 million in Q1 2020.
  • Average Other Accumulated Expenses over 5 years is $13.0 million, with a median of $10.9 million recorded in 2019.
  • Peak YoY movement for Other Accumulated Expenses: soared 249.04% in 2019, then tumbled 56.58% in 2022.
  • A 5-year view of Other Accumulated Expenses shows it stood at $11.9 million in 2019, then surged by 108.83% to $24.8 million in 2020, then rose by 22.67% to $30.4 million in 2021, then crashed by 56.58% to $13.2 million in 2022, then soared by 89.32% to $25.0 million in 2023.
  • Per Business Quant, the three most recent readings for ESPR's Other Accumulated Expenses are $25.0 million (Q4 2023), $13.2 million (Q4 2022), and $30.4 million (Q4 2021).